(Total Views: 297)
Posted On: 06/07/2018 4:38:38 PM
Post# of 72446
I received this copy of a PR in my PM box.
At first glance it seems benign but reading through it , it supports your's and our
notion that Leo is not obliged to release the trial data according to any governing time frame.
As you can see at the end,the words "expects" and "approximately"obviously connote the lack of "urgency" in any timely releasing of the data to the public.
That said,Leo could have had the data from this trial a lot longer than we think and using it in the negotiations.
"Shorty" is going to get FRIED and NO ONE AMONG US wants it more than LEO.
BEVERLY, MA--(Marketwired - May 11, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the clinical database for the Phase 2 clinical trial of Prurisol for the treatment of mild-to-moderate chronic plaque psoriasis is expected to be "unblinded" next week. Once the blind is removed, data from each of the four arms of the trial (one placebo arm, three oral dosing regimens of Prurisol) will be reviewed and analyzed to evaluate the safety and efficacy of Prurisol. Cellceutix expects to release top-line data from the study approximately one week after the blind is removed.
At first glance it seems benign but reading through it , it supports your's and our
notion that Leo is not obliged to release the trial data according to any governing time frame.
As you can see at the end,the words "expects" and "approximately"obviously connote the lack of "urgency" in any timely releasing of the data to the public.
That said,Leo could have had the data from this trial a lot longer than we think and using it in the negotiations.
"Shorty" is going to get FRIED and NO ONE AMONG US wants it more than LEO.
BEVERLY, MA--(Marketwired - May 11, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the clinical database for the Phase 2 clinical trial of Prurisol for the treatment of mild-to-moderate chronic plaque psoriasis is expected to be "unblinded" next week. Once the blind is removed, data from each of the four arms of the trial (one placebo arm, three oral dosing regimens of Prurisol) will be reviewed and analyzed to evaluate the safety and efficacy of Prurisol. Cellceutix expects to release top-line data from the study approximately one week after the blind is removed.
(2)
(0)
